Behavioral dysfunction but not wasting in cancer cachexia is driven by altered tryptophan metabolism

Cancer is often thought of as a disease that simply grows out of control, but for many patients, the most devastating consequence is not the tumor itself, but a wasting syndrome called cachexia. This condition strips the body of its fat and muscle, leaving patients weak, exhausted, and unable to eat. It is a complex state where the body seems to turn against itself, driven by signals from the tumor that disrupt normal metabolism and energy use. Beyond the physical decline, patients frequently suffer from a profound lack of motivation, fatigue, and symptoms that look very much like severe depression. For decades, scientists have struggled to understand why this happens and how to stop it, often assuming that the loss of appetite and the loss of muscle were part of the same unstoppable process.

A new study from researchers at Rutgers University and Princeton University has peeled back the layers of this mystery using mouse models of pancreatic cancer, one of the most aggressive forms of the disease. The team discovered that the body's response to cancer is not a single, unified collapse, but rather a split path. They found that the chemical signals causing the loss of appetite and the feeling of despair are driven by a specific change in how the body processes a nutrient called tryptophan. However, the deadly wasting of muscle and fat appears to be driven by a different set of forces that remain untouched by fixing the appetite or the mood. This distinction is crucial because it suggests that while we may be able to improve the quality of life for patients by treating their behavior and energy, the lethal wasting might require a completely different approach.

The researchers began by observing mice with pancreatic tumors, tracking their weight, food intake, and activity levels as the disease progressed. They confirmed what is already known: the mice lost significant amounts of fat and muscle, ate less, and moved far less than healthy mice. But they wanted to know what was happening inside the body to cause these changes. They looked at the chemical landscape across the entire body, from the blood to the liver, the spleen, and the tumors themselves. What they found was a dramatic shift in how the body handled tryptophan. In a healthy body, tryptophan is a building block that can be turned into serotonin, a chemical that helps regulate mood, sleep, and the desire to eat. In the cancerous mice, the body stopped making serotonin and instead diverted almost all of the tryptophan into a different pathway that produced a substance called kynurenine.

This diversion created a double problem. First, the lack of serotonin meant the mice had no desire to eat and no motivation to move, leading to the behavioral symptoms of depression and anorexia. Second, the buildup of kynurenine activated a specific receptor in the body, known as the aryl hydrocarbon receptor, which further suppressed feeding and activity. The researchers proved this by giving the mice a drug called fluoxetine, which is commonly used to treat depression in humans by boosting serotonin levels. The treated mice started eating more and running on their wheels again, behaving much more like healthy animals. Their energy balance improved because they were taking in more calories. Yet, despite this dramatic improvement in behavior and appetite, the mice continued to lose weight. Their fat and muscle still wasted away, and they did not live any longer than the untreated mice.

To test if the kynurenine buildup was the culprit behind the behavioral issues, the team used a different drug to block the enzyme that creates kynurenine. This also restored the mice's appetite and activity levels without stopping the weight loss. When they combined both treatments—boosting serotonin and blocking kynurenine—the mice not only ate and moved better, but they also managed to hold onto some of their fat mass. However, even this powerful combination could not save the mice from the ultimate fate of the disease; their tumors continued to grow, and their survival time remained unchanged.

The study also revealed that the body was in a state of energy crisis across multiple organs. The cells in the liver, muscle, and spleen were running low on their internal energy reserves, a sign that the body was struggling to meet the massive demands of the cancer. The researchers tried to fix this by feeding the mice a diet with ten times the normal amount of tryptophan, hoping that having more raw material would help the body make the serotonin it needed. Instead, the extra tryptophan only made the problem worse. The tumors grabbed the excess nutrient and turned it into even more kynurenine, accelerating the buildup of the harmful substance and causing the mice to die faster. This showed that simply adding more of the nutrient was not the solution; the body's machinery had been hijacked to process it in a harmful way.

The findings suggest that cancer cachexia is not a single disease but a collection of separate problems. The tumor sends out signals that cause the liver and immune system to become inflamed, which in turn reprograms the body's metabolism. This reprogramming creates a bottleneck where tryptophan is forced into the kynurenine pathway, starving the brain of serotonin and triggering the loss of appetite and the feeling of hopelessness. While this pathway is responsible for the terrible behavioral symptoms, the actual destruction of muscle and fat seems to be driven by other, more direct mechanisms that are not affected by fixing the mood or the appetite.

This work changes how we might think about treating cancer patients. It indicates that we can likely improve their daily lives, helping them eat, move, and feel less depressed, without necessarily stopping the physical wasting that leads to death. The researchers showed that by targeting the specific chemical pathways involved in mood and appetite, they could restore a sense of normalcy to the animals' behavior. However, the lethal aspect of the disease, the actual consumption of the body's tissues, remained stubbornly resistant to these interventions. The study concludes that while we may be able to treat the suffering associated with cancer, the fatal wasting requires new strategies that go beyond simply fixing the chemical imbalance of serotonin and kynurenine. The path forward lies in understanding that these are two distinct battles, and winning one does not guarantee victory in the other.